表2
分析场景 | 敏感 | 特异性 | 正LR | 负LR | 多尔 | 异质性* |
---|
所有研究
| 0.42 (0.21, 0.67)
| 0.99 (0.96, 1.00)
| 58.2 ( 9.8, 345.9)
| 0.58 (0.38, 0.89)
| 100 (15, 663)
| 98 (98, 99)
|
无异常值的所有研究
| 0.37 (0.16, 0.65)
| 0.99 (0.96, 1.00)
| 65.4 (8.4, 511.4)
| 0.63 (0.42, 0.96)
| 104 (11, 956)
| 94 (89, 99)
|
分组:CEA
| 0.31 (0.10, 0.64)
| 0.94 (0.87, 0.98)
| 5.4 (2.1, 14.0)
| 0.73 (0.49, 1.09)
| 7(2,26)
| 98 (96, 99)
|
分组:CK-19
| 0.27 (0.06, 0.67)
| 0.95(0.90,0.98)
| 5.4 (1.7, 16.4)
| 0.77 (0.50, 1.19)
| 7 (2, 31)
| 97 (96, 99)
|
分组:CK-20
| 0.25 (0.13, 0.43)
| 0.95 (0.89, 0.98)
| 4.9 (1.6, 14.9)
| 0.79 (0.64, 0.98)
| 6 (2, 23)
| 0(0-100)
|
分组:阶段1
| 0.22 (0.06, 0.56)
| 0.95 (0.89, 0.98)
| 4.3 (1.1, 17.7)
| 0.82 (0.59, 1.15)
| 5 (1, 29)
| 91 (83, 100)
|
分组:阶段2
| 0.40 (0.14, 0.73)
| 0.96 (0.90, 0.98)
| 9.7 (4.5, 20.9)
| 0.62 (0.37, 1.07)
| 15 (5, 48)
| 93 (86, 99)
|
分组:阶段3
| 0.46 (0.16, 0.80)
| 0.95 (0.90, 0.98)
| 9.4 (3.4, 25.9)
| 0.56 (0.28, 1.15)
| 17 (3, 83)
| 94 (89, 99)
|
分组:第4阶段
| 0.63(0.43,0.79)
| 0.97 (0.95, 0.98)
| 20.6 (11.2, 38.0)
| 0.38 (0.23, 0.64)
| 54(21338)
| 71 (35,100)
|
分组:1-3阶段
| 0.30 (0.09, 0.64)
| 0.96 (0.91, 0.98)
| 6.9 (2.2,21.3)
| 0.73 (0.48, 1.12)
| 9 (2, 42)
| 97 (95, 99)
|
分组:基于PCR的分析
| 0.39 (0.20, 0.60)
| 0.94(0.90,0.96)
| 6.1 (3.6, 10.4)
| 0.94 (0.90, 0.96)
| 9 (4, 21)
| 96 (95, 97)
|
亚组:免疫分析 | 0.82 (0.43, 1.00) | 1.00 (0.98, 1.00) | 74.5 (15.0,368.9) | 0.335 (0.12-0.97) | 340.9 (23.26,4996.7) | 93 (88, 97) |